MedPage Today on MSN
GLP-1s for addiction; DEA's ketamine crackdown; ADHD and social media
News and commentary from the psychiatry world ...
MedPage Today on MSN
FDA's Psychedelic Guidance; Mass Shootings and Car Crashes; ADHD Drug Misuse Down
News and commentary from the psychiatry world ...
Adults with ADHD and comorbid anxiety experienced improvements in both with centanafadine, according to a press release from ...
GlobalData on MSN
Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial
Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.
20hon MSN
How telehealth is fuelling a surge in ADHD scripts in a business model that benefits the rich
Seeing a psychiatrist via telehealth became easier from January 2022. That’s when Medicare-reimbursed telepsychiatry ...
A federal appeals court on Monday revived hundreds of lawsuits where plaintiffs claimed to have evidence of a link between ...
U.S. Commercial launch of Gen 2 Monarch System commencing today, July 21, 2026Gen 2 Monarch device provides an enhanced patient experience while ...
Reassuring evidence on acetaminophen’s safety in pregnancy keeps growing, with another study that compares siblings with ...
ADHD patients deserved a more consistent, safe and manageable medication experience. Imagining a better way forward, they approached some of the pharmaceutical industry’s biggest players, who ...
Misuse of stimulant medications for attention-deficit/hyperactivity disorder (ADHD) has declined sharply. In 2023, approximately 3.7% of adults younger than 30 misused these medications, down from 7.5 ...
A bill signed into law this week changes the rules around about stimulants commonly prescribed for attention deficit ...
Misuse of prescription drugs used to treat ADHD has dropped sharply among American adults, according to a new study published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results